This morning, FDA announced that it will now release complete response letters (CRLs) “promptly after they are issued to sponsors.” Alongside that announcement, it released 89 previously unpublished CRLs that were issued since 2024.That tranche includes the CRL that the agency issued to Lykos Therapeutics last August, when it rejected the company’s MDMA for PTSD application.
